Matt Kazan provides strategic advice to health plan and life sciences clients navigating the complex legislative and regulatory policy environment, with a particular expertise in Medicare Advantage and Medicare Part D. Prior to joining Avalere, Matt spent over a decade on the U.S. Senate Committee on Finance health staff under Senators Max Baucus and Ron Wyden.

As senior health policy adviser, Matt was the primary policy adviser on policy issues, including Medicare Advantage, Medicare Part D and all drug reimbursement under Medicare, chronic disease, dual eligibles, post-acute care, the Medicare Shared Savings Program, and Medicare and Medicaid program integrity. During his tenure, Matt was involved in a variety of major legislative efforts including the Affordable Care Act, the Bipartisan Budget Act of 2018, the Medicare Access and CHIP Reauthorization Act of 2015, the Children’s Health Insurance Program Reauthorization Act of 2009, and the American Recovery and Reinvestment Act. Matt holds an undergraduate degree from the University of Denver and a Master of Public Policy from the George Washington University.

Authored Content


Avalere analysis finds that payment to Medicare Advantage (MA) plans for end-stage renal disease (ESRD) patients in highly populated regions may be significantly below actual patient costs.

A shifting policy landscape and emerging market forces could introduce significant disruption in the kidney care space in the coming years. Understanding the risks and opportunities that these changes may present will be critical for patients, providers, payers, and manufacturers alike.